16.12
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums | 2025-06-30 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
Operating Expenses |
9.92%
127.22
|
115.74 | 94.28 | 80.88 | 61.55 |
Income/Loss From Continuing Operations Before Tax |
9.78%
-119.70
|
-109.04 | -87.07 | -75.09 | -51.53 |
Income Tax Expense/Benefit |
1,071%
0.913
|
0.078 | 0.077 | 0.232 | -0.108 |
Income/Loss From Continuing Operations After Tax |
10.53%
-120.61
|
-109.12 | -87.15 | -75.32 | -51.42 |
|
10.53%
-120.61
|
-109.12 | -87.15 | -75.32 | -51.42 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
16.66%
170.87
|
146.47 | 146.09 | 2.5233 | 144.52 |
Diluted Average Shares |
16.66%
170.87
|
146.47 | 146.09 | 2.5233 | 144.52 |
Basic Earnings Per Share |
4.05%
-0.71
|
-0.74 | -0.60 | -0.52 | -0.36 |
Diluted Earnings Per Share |
4.05%
-0.71
|
-0.74 | -0.60 | -0.52 | -0.36 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):